The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation |
|---|---|
| Study Drug | VX-809 and VX-770 |
| Type of Study Drug | CFTR modulation |
| Study Title | A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone and in Combination With VX-770 in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation |
| Study Phase | 2 |
| Study Sponsor | Vertex Pharmaceuticals Incorporated |
http://clinicaltrials.gov/ct2/show/study/NCT01225211 (link is external) | |
| Participating ECFS-CTN sites | Belgium: Leuven France: Lyon, West-Paris (Cochin) Germany: Berlin, Cologne, Frankfurt Sweden: Gothenburg UK: London |
| Age | 18 years and older |